Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additions
Revuforj and Niktimvo both posted double-digit year-over-year net revenue growth as Syndax laid out new trial timelines for its expanded pipeline.
SEC filing
Latest
1 story